1. Mastroianni AC, Faden R, & Federman D. (Eds.). Women and health research: ethical and legal issues of including women in clinical studies (vol. 1). Washington: National Academies Press. 1994.
2. Hennekens CH. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med. 1989;321(3):129–35.
3. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;31;352(13):1293-304.
4. Heinrich, J., Gahart, M. T., Rowe, E. J., & Bradley, L. (2001). Drug safety: most drugs withdrawn in recent years had greater health risks for women. A letter to The Honorable Tom Harkin, The Honorable Olympia J. Snowe, The Honorable Barbara A. Mikulski, United States Senate, The Honorable Henry Waxman, House of Representatives. Washington DC: United States General Accounting Office.
5. US Food and Drug Administration. (2013). Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist). Silver Spring, MD: Drug Safety Communications.